Amy C. Peterson, CMO, Immuno-oncology at BeiGene, Ltd. (BGNE), sold 72,500 shares at $122.86 ($8.8M) on 2018-11-08, disclosed to the SEC on 2018-11-13.
Open-market sale of $8.8M BGNE by CMO, Immuno-oncology. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $122.86 | 466 | $57K | 0.7% |
| 2 | $122.86 | 466 | $57K | 0.7% |
| 3 | $124.48 | 2,423 | $302K | 3.4% |
| 4 | $124.48 | 2,423 | $302K | 3.4% |
| 5 | $126.08 | 3,949 | $498K | 5.7% |
| 6 | $126.08 | 3,949 |
| $498K |
| 5.7% |
| 7 | $126.72 | 7,673 | $972K | 11.1% |
| 8 | $126.72 | 7,673 | $972K | 11.1% |
| 9 | $127.61 | 200 | $26K | 0.3% |
| 10 | $127.61 | 200 | $26K | 0.3% |
| 11 | $118.64 | 4,031 | $478K | 5.5% |
| 12 | $118.64 | 4,031 | $478K | 5.5% |
| 13 | $119.27 | 1,725 | $206K | 2.4% |
| 14 | $119.27 | 1,725 | $206K | 2.4% |
| 15 | $120.63 | 2,100 | $253K | 2.9% |
| 16 | $121.71 | 2,898 | $353K | 4.0% |
| 17 | $121.71 | 2,898 | $353K | 4.0% |
| 18 | $122.55 | 2,046 | $251K | 2.9% |
| 19 | $122.55 | 2,046 | $251K | 2.9% |
| 20 | $123.75 | 322 | $40K | 0.5% |
| 21 | $123.75 | 322 | $40K | 0.5% |
| 22 | $125.97 | 100 | $13K | 0.1% |
| 23 | $111.10 | 2,958 | $329K | 3.8% |
| 24 | $111.10 | 2,958 | $329K | 3.8% |
| 25 | $112.18 | 4,000 | $449K | 5.1% |
| 26 | $113.03 | 2,527 | $286K | 3.3% |
| 27 | $113.03 | 2,527 | $286K | 3.3% |
| 28 | $113.92 | 1,173 | $134K | 1.5% |
| 29 | $113.92 | 1,173 | $134K | 1.5% |
| 30 | $114.96 | 700 | $80K | 0.9% |
| 31 | $116.56 | 500 | $58K | 0.7% |
| 32 | $117.61 | 109 | $13K | 0.1% |
| 33 | $117.61 | 109 | $13K | 0.1% |
| 34 | $121.56 | 100 | $12K | 0.1% |
| Total | $120.70 avg | 72,500 | $8.8M | 100% |
| Filing → |
| CTMX | SELL | 2022-07-21 | $11K | — | Filing → |
| BGNE | SELL | 2018-12-19 | $4.5M | — | Filing → |
| BGNE | SELL | 2018-08-24 | $1.3M | — | Filing → |